Results 141 to 150 of about 131,155 (303)

Reminescences about my research on platelet membrane glycoproteins

, 2016
Makoto Handa
openalex   +2 more sources

Phase IIb Trial for the Palliative Treatment of Patients With Primary Hepatic Malignancy Unable to Receive Curative Treatment: Efficacy of Colchicine

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This trial was to evaluate the efficacy and the safety of colchicine for the palliative treatment of patients with primary hepatic malignancy unable to receive curative treatment. Forty hepatocellular carcinoma (HCC) patients and two intrahepatic cholangiocarcinoma (ICC) patients signed the informed consents.
Zu‐Yau Lin, Ming‐Lun Yeh, Po‐Cheng Liang, Shinn‐Cherng Chen, Chung‐Feng Huang, Jee‐Fu Huang, Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang   +8 more
wiley   +1 more source

Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders [PDF]

, 2000
Morten Krogh Jensen, Peter de Nully Brown, B. Lund, Ove Juul Nielsen, Hans Carl Hasselbalch   +4 more
openalex   +1 more source

Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy

Medicine Bulletin, EarlyView.
ABSTRACT Recently, immune checkpoint inhibitors (ICIs), particularly PD‐1/PD‐L1 and CTLA‐4 inhibitors, have revolutionized cancer treatment, significantly improving survival rates for various malignancies. However, ICI therapies targeting single checkpoints on T cells still face numerous challenges, such as low response rates and post‐treatment ...
Yangyang Li, Zizhen Kang, Yanyun Du
wiley   +1 more source

alpha-Actinin and membrane glycoprotein IIIa are different proteins in human blood platelets.

, 1982
Barbara G. Langer, L L Leung, Patricia Gonnella, V T Nachmias, Ralph L. Nachman, Frank A. Pepe   +5 more
openalex   +2 more sources

A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka- platelets lack detectable GPIV (CD36) [PDF]

, 1990
Naomasa Yamamoto, Hisami Ikeda, NN Tandon, J Herman, Yoshiaki Tomiyama, Takako Mitani, S Sekiguchi, Robert H. Lipsky, Urszula Kralisz, GA Jamieson   +9 more
openalex   +1 more source

Disarming the Hsp70–Bim Alliance: Small‐Molecule and Peptidic Disruptors of a Chaperone‐Apoptotic Switch in Cancer

ChemistryOpen, EarlyView.
Targeting a nucleotide‐sensitive groove on Hsp70 that binds the Bim BH3 helix, we integrate structures, biophysics, and SAR from peptides, fragments, and phenalene‐dicarbonitrile “wedges.” These disrupt the Hsp70–Bim complex with sub‐µM cellular engagement and in vivo activity while sparing Hsp90/mortalin.
Emadeldin M. Kamel, Mohammed Al‐zharani, Lina M. Alneghery, Noha A. Ahmed, Faris F. Aba Alkhayl, Al Mokhtar Lamsabhi   +5 more
wiley   +1 more source

Structure and Function of Platelet Membrane Glycoprotein V

, 1994
Kingo Fujimura
openalex   +2 more sources

Surface Expression of Major Membrane Glycoproteins on Resting and Activated Neonatal Platelets 224 [PDF]

, 1996
Jan Šimák, Karel Holada, Jan Janota, Zbyněk Straňák   +3 more
openalex   +1 more source

Oncogenic H‐Ras Reprograms Madin‐Darby Canine Kidney (MDCK) Cell‐Derived Midbody Remnant Proteome Following Epithelial‐Mesenchymal Transition

PROTEOMICS, EarlyView.
ABSTRACT Epithelial‐mesenchymal transition (EMT) is a fundamental, dynamic cellular process involved in embryonic development, metastasis, organ fibrosis, and tissue regeneration. To define the molecular landscape of secreted midbody remnants (MBRs) to the EMT process, a proteome analysis of MBRs released from Madin–Darby canine kidney (MDCK) cells and
Adnan Shafiq, Alin Rai, Rong Xu, Maoshan Chen, Wittaya Suwakulsiri, David W. Greening, Richard J. Simpson   +6 more
wiley   +1 more source